Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefaclor into the millennium.

W Brumfitt1, J M Hamilton-Miller

  • 1Department of Medical Microbiology, Royal Free Hospital and Royal Free and University College Medical School, London, UK.

Journal of Chemotherapy (Florence, Italy)
|August 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The susceptibility of nosocomial pathogens to ceftazidime.

The Journal of antimicrobial chemotherapy·2009
Same author

Activities of ciprofloxacin, levofloxacin, ofloxacin and sparfloxacin against speciated coagulase-negative staphylococci sensitive and resistant to fluoroquinolones.

International journal of antimicrobial agents·2008
Same author

Vancomycin-resistant Staphylococcus aureus: a real and present danger?

Infection·2002
Same author

Identity and antibiotic susceptibility of enterobacterial flora of salad vegetables.

International journal of antimicrobial agents·2001
Same author

Overview of cefixime use in community-acquired infections.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2001
Same author

Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2001
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

Cefaclor, a cephalosporin antibiotic, effectively inhibits bacterial cell wall synthesis and shows favorable in vitro activity. Clinical trials confirm its efficacy in treating common infections with a good safety profile.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Cephalosporins represent a significant class of beta-lactam antibiotics.
  • Cefaclor is a widely used oral antibiotic derived from cephalosporins.

Purpose of the Study:

  • To review the discovery, development, and clinical application of cefaclor.
  • To evaluate cefaclor's efficacy, pharmacokinetics, safety, and pharmaco-economics.

Main Methods:

  • Review of literature on cephalosporins and cefaclor.
  • Analysis of in vitro activity data against common bacterial pathogens.
  • Examination of pharmacokinetic properties and clinical trial results.
  • Assessment of adverse event incidence and patient compliance.
  • Consideration of pharmaco-economic factors.

Related Experiment Videos

Main Results:

  • Cefaclor exhibits broad-spectrum activity by inhibiting bacterial cell wall synthesis.
  • Its in vitro efficacy is comparable to other beta-lactam antibiotics.
  • Pharmacokinetic data support an 8-hourly dosing schedule; a delayed-release formulation allows twice-daily dosing.
  • Clinical trials demonstrate efficacy in respiratory, urinary tract, and soft tissue infections.
  • Cefaclor is associated with a low incidence of adverse events, enhancing patient compliance.

Conclusions:

  • Cefaclor is an effective and well-tolerated antibiotic for common bacterial infections.
  • Its pharmacokinetic profile and favorable safety contribute to its therapeutic utility.
  • Both standard and delayed-release formulations offer viable treatment options.